Urogen Pharma Ltd. revenue
Urogen Pharma Ltd.'s revenue was $110m in fiscal 2025, up 21.4% on the year before. Since fiscal 2016 ($17.5m) it has grown at a compound 22.6% a year. Over the last twelve months it was $189m.
Revenue history
| Fiscal year | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18 | 8 | 1 | 0 | 12 | 48 | 64 | 83 | 90 | 110 | 189 |
| Growth on the year before | — | −53.5% | −86.2% | −98.4% | +>999% | +307.2% | +34.0% | +28.5% | +9.3% | +21.4% | — |
| Gross profit | 18 | 8 | −1 | 0 | 11 | 43 | 57 | 73 | 82 | 97 | 171 |
| Gross margin | 99.8% | 92.6% | −59.8% | 100.0% | 91.4% | 89.3% | 88.1% | 88.7% | 90.2% | 88.7% | 90.8% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Jelmyto | $94M | 85.6% | ▲ 4.0% |
| Zusduri | $15.8M | 14.4% | — |
From Urogen Pharma Ltd.'s 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Urogen Pharma Ltd. | $189m | 100.3% | 37.6% |
| Arbutus Biopharma Corp | $182m | 1078.8% | 97.6% |
| Valneva SE | $197m | 7.6% | — |
| Nuvation Bio Inc. | $170m | 1083.6% | — |
| Immunitybio, Inc. | $166m | 192.9% | 554.3% |
| Akebia Therapeutics, Inc. | $219m | 7.5% | 2.9% |
Compare with peers
- Arbutus Biopharma Corp revenue
- Valneva SE revenue
- Nuvation Bio Inc. revenue
- Immunitybio, Inc. revenue
- Akebia Therapeutics, Inc. revenue
Head to head: ABUS vs URGNURGN vs VALNNUVB vs URGN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies